Floatz logo

FLUDEOXYGLUCOSE

Lung Non-Small Cell Carcinoma

Alliance for Clinical Trials in OncologySmall moleculePhase 3Active
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
89/ 100

Competitive context

1205 Active assets in the Lung Non-Small Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BBB
Necitumumab
Jonsson Comprehensive Cancer Center
Phase 3BBB
Glumetinib
Shanghai JMT-Bio Inc.
Phase 3BBB
Veliparib
AbbVie
Phase 3BBB
Icotinib
The First Affiliated Hospital of Guangzhou Medical University
Phase 4BBB

View all 50 →

Same molecule, other indications

FLUDEOXYGLUCOSE is also rated in:

Recurrent Adult Brain TumorDormant
BB
Indicative ·
71 / 100
View asset →
prostate carcinomaDormant
BB
Indicative ·
69 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →